Neuroinflammation and neurodegeneration are key processes that mediate the development and progression of neurological diseases.However,the mechanisms modulating these processes in different diseases remain incomplete...Neuroinflammation and neurodegeneration are key processes that mediate the development and progression of neurological diseases.However,the mechanisms modulating these processes in different diseases remain incompletely understood.Advances in single cell based multi-omic analyses have helped to identify distinct molecular signatures such as Lgals3 that is associated with neuroinflammation and neurodegeneration in the central nervous system(CNS).Lgals3 encodes galectin-3(Gal3),aβ-galactoside and glycan binding glycoprotein that is frequently upregulated by reactive microglia/macrophages in the CNS during various neurological diseases.While Gal3 has previously been associated with non-CNS inflammatory and fibrotic diseases,recent studies highlight Gal3 as a prominent regulator of inflammation and neuroaxonal damage in the CNS during diseases such as multiple sclerosis,Alzheimer’s disease,and Parkinson’s disease.In this review,we summarize the pleiotropic functions of Gal3 and discuss evidence that demonstrates its detrimental role in neuroinflammation and neurodegeneration during different neurological diseases.We also consider the challenges of translating preclinical observations into targeting Gal3 in the human CNS.展开更多
<strong>Background:</strong><span style="font-family:;" "=""><span style="font-family:Verdana;"> Acute coronary syndrome (ACS) is a very common cause</span...<strong>Background:</strong><span style="font-family:;" "=""><span style="font-family:Verdana;"> Acute coronary syndrome (ACS) is a very common cause</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">of hospitalizations worldwide each year. Despite Troponin is considered the gold standard in diagnosis of ACS</span></span><span style="font-family:Verdana;">.</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> Several molecules have been investigated to identify predictive biomarkers of diagnosis. Among these, Galectin-3 has emerged as a promising diagnostic biomarker of (ACS). We aimed to evaluate galectin-3 levels in patients with acute coronary syndrome (ACS) and its relation to severity of coronary artery disease. </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:Verdana;">Seventy two patients with ACS who underwent primary</span><b></b><span style="font-family:Verdana;">percutaneous coronary intervention (PCI) and 20 age-matched healthy controls were enrolled in our study .The severity of coronary artery disease and the burden of atherosclerosis was assessed with Gensini score and with the number of affected vessels. Galectin-3 levels were measured on admission by using ELISA with a commercially kit. </span><b><span style="font-family:Verdana;">Result: </span></b><span style="font-family:Verdana;">The mean age of the observational case control study was 55.9 ±</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">11.9 and 68 patients (73.9%) of the study were male. Median galectin-3 levels were significantly higher in ACS patients (20.25 ng/mL [11.9 - 39.0] vs. 8.9 ng/mL [4.6 - 24.0], P = 0.001). Patients were classified into three groups according to the number of involved vessels. Median galectin-3 levels were also significantly differen</span></span><span style="font-family:Verdana;">t</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> among groups (one vessel: 18.9 (12 - 35.2) ng/mL, two vessels: 19 (11.9 - 35) ng/mL, three vessels 32 (12 - 39) ng/mL, P = 0.007). There was a strong correlation between galectin-3 levels and Gensini score (r = 0.500, P = 0.001). </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> Galectin-3 levels were elevated in patients with ACS and there</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">was a strong correlation between galectin-3 and severity of coronary artery disease.</span></span>展开更多
目的探讨T细胞免疫球蛋白黏蛋白分子(Tim-3)及半乳糖凝集素-9(Galectin-9)的表达与肿瘤T细胞免疫在鼻咽癌中的临床意义。方法在癌症基因组图谱计划(The Cancer Genome Atlas,TCGA)数据库中查找Tim-3在各种肿瘤组织中的表达情况,选取与...目的探讨T细胞免疫球蛋白黏蛋白分子(Tim-3)及半乳糖凝集素-9(Galectin-9)的表达与肿瘤T细胞免疫在鼻咽癌中的临床意义。方法在癌症基因组图谱计划(The Cancer Genome Atlas,TCGA)数据库中查找Tim-3在各种肿瘤组织中的表达情况,选取与鼻咽癌患者免疫密切相关的基因Tim-3及其配体Galectin-9作为研究基因;收集2018年3月~2022年3月广西壮族自治区民族医院收治的65例鼻咽癌患者的肿瘤组织、同期65例鼻咽部炎性标本组织及对应鼻咽癌患者放疗前后应用免疫细胞病理芯片技术检测的外周血T细胞亚群变化的数据,并做随访观察。结果生物信息学分析TCGA数据库中鼻咽癌的测序数据,结果显示,Tim-3在大部分肿瘤组织中呈高表达,在鼻咽癌组织中较癌旁正常组织表达水平显著上调,Tim-3及其配体Galectin-9在癌组织中的表达呈正相关;免疫组化结果显示,鼻咽癌组织中Tim-3和Galectin-9的表达水平均显著高于鼻咽部炎性组织(P<0.05);鼻咽癌组织中Tim-3和Galectin-9高表达与淋巴结受累(P<0.05)以及更晚的TNM分期(P<0.05)紧密相关;Tim-3和Galectin-9的表达水平与患者年龄、性别及EB病毒感染等因素无关(P>0.05);Tim-3和Galectin-9在鼻咽癌中的表达呈正相关(r=0.313,P=0.011);随访发现,Tim-3和Galectin-9的高表达可能与鼻咽癌的不良预后相关;鼻咽癌患者放疗前3天和放疗后7天的T淋巴细胞亚群检测显示,CD4+、CD4+/CD8+较放疗前显著下降(P<0.05),CD3+与CD8+变化差异无统计学意义(P>0.05);Tim-3和Galectin-9蛋白阳性组患者放疗敏感度明显高于于Tim-3和Galectin-9阴性组(P<0.05)。结论Tim-3/Galectin-9信号通路在鼻咽癌发生、发展和转移中起重要作用,T细胞免疫在鼻咽癌治疗中发挥重要作用。联合检测鼻咽癌组织中Tim-3和Galectin-9及T细胞亚群的变化可能为临床评估肿瘤监测病情及肿瘤免疫治疗提供新参数。展开更多
文摘Neuroinflammation and neurodegeneration are key processes that mediate the development and progression of neurological diseases.However,the mechanisms modulating these processes in different diseases remain incompletely understood.Advances in single cell based multi-omic analyses have helped to identify distinct molecular signatures such as Lgals3 that is associated with neuroinflammation and neurodegeneration in the central nervous system(CNS).Lgals3 encodes galectin-3(Gal3),aβ-galactoside and glycan binding glycoprotein that is frequently upregulated by reactive microglia/macrophages in the CNS during various neurological diseases.While Gal3 has previously been associated with non-CNS inflammatory and fibrotic diseases,recent studies highlight Gal3 as a prominent regulator of inflammation and neuroaxonal damage in the CNS during diseases such as multiple sclerosis,Alzheimer’s disease,and Parkinson’s disease.In this review,we summarize the pleiotropic functions of Gal3 and discuss evidence that demonstrates its detrimental role in neuroinflammation and neurodegeneration during different neurological diseases.We also consider the challenges of translating preclinical observations into targeting Gal3 in the human CNS.
文摘<strong>Background:</strong><span style="font-family:;" "=""><span style="font-family:Verdana;"> Acute coronary syndrome (ACS) is a very common cause</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">of hospitalizations worldwide each year. Despite Troponin is considered the gold standard in diagnosis of ACS</span></span><span style="font-family:Verdana;">.</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> Several molecules have been investigated to identify predictive biomarkers of diagnosis. Among these, Galectin-3 has emerged as a promising diagnostic biomarker of (ACS). We aimed to evaluate galectin-3 levels in patients with acute coronary syndrome (ACS) and its relation to severity of coronary artery disease. </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:Verdana;">Seventy two patients with ACS who underwent primary</span><b></b><span style="font-family:Verdana;">percutaneous coronary intervention (PCI) and 20 age-matched healthy controls were enrolled in our study .The severity of coronary artery disease and the burden of atherosclerosis was assessed with Gensini score and with the number of affected vessels. Galectin-3 levels were measured on admission by using ELISA with a commercially kit. </span><b><span style="font-family:Verdana;">Result: </span></b><span style="font-family:Verdana;">The mean age of the observational case control study was 55.9 ±</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">11.9 and 68 patients (73.9%) of the study were male. Median galectin-3 levels were significantly higher in ACS patients (20.25 ng/mL [11.9 - 39.0] vs. 8.9 ng/mL [4.6 - 24.0], P = 0.001). Patients were classified into three groups according to the number of involved vessels. Median galectin-3 levels were also significantly differen</span></span><span style="font-family:Verdana;">t</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> among groups (one vessel: 18.9 (12 - 35.2) ng/mL, two vessels: 19 (11.9 - 35) ng/mL, three vessels 32 (12 - 39) ng/mL, P = 0.007). There was a strong correlation between galectin-3 levels and Gensini score (r = 0.500, P = 0.001). </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> Galectin-3 levels were elevated in patients with ACS and there</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">was a strong correlation between galectin-3 and severity of coronary artery disease.</span></span>
文摘目的探讨T细胞免疫球蛋白黏蛋白分子(Tim-3)及半乳糖凝集素-9(Galectin-9)的表达与肿瘤T细胞免疫在鼻咽癌中的临床意义。方法在癌症基因组图谱计划(The Cancer Genome Atlas,TCGA)数据库中查找Tim-3在各种肿瘤组织中的表达情况,选取与鼻咽癌患者免疫密切相关的基因Tim-3及其配体Galectin-9作为研究基因;收集2018年3月~2022年3月广西壮族自治区民族医院收治的65例鼻咽癌患者的肿瘤组织、同期65例鼻咽部炎性标本组织及对应鼻咽癌患者放疗前后应用免疫细胞病理芯片技术检测的外周血T细胞亚群变化的数据,并做随访观察。结果生物信息学分析TCGA数据库中鼻咽癌的测序数据,结果显示,Tim-3在大部分肿瘤组织中呈高表达,在鼻咽癌组织中较癌旁正常组织表达水平显著上调,Tim-3及其配体Galectin-9在癌组织中的表达呈正相关;免疫组化结果显示,鼻咽癌组织中Tim-3和Galectin-9的表达水平均显著高于鼻咽部炎性组织(P<0.05);鼻咽癌组织中Tim-3和Galectin-9高表达与淋巴结受累(P<0.05)以及更晚的TNM分期(P<0.05)紧密相关;Tim-3和Galectin-9的表达水平与患者年龄、性别及EB病毒感染等因素无关(P>0.05);Tim-3和Galectin-9在鼻咽癌中的表达呈正相关(r=0.313,P=0.011);随访发现,Tim-3和Galectin-9的高表达可能与鼻咽癌的不良预后相关;鼻咽癌患者放疗前3天和放疗后7天的T淋巴细胞亚群检测显示,CD4+、CD4+/CD8+较放疗前显著下降(P<0.05),CD3+与CD8+变化差异无统计学意义(P>0.05);Tim-3和Galectin-9蛋白阳性组患者放疗敏感度明显高于于Tim-3和Galectin-9阴性组(P<0.05)。结论Tim-3/Galectin-9信号通路在鼻咽癌发生、发展和转移中起重要作用,T细胞免疫在鼻咽癌治疗中发挥重要作用。联合检测鼻咽癌组织中Tim-3和Galectin-9及T细胞亚群的变化可能为临床评估肿瘤监测病情及肿瘤免疫治疗提供新参数。
